A Phase 3 interventional study of Cagrilintide and Semaglutide in Overweight and Obesity, sponsored by Novo Nordisk A/S. Recruiting at 121 sites in 26 countries. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.
Among the 36 studies testing cagrilintide in Obesity, this one is the 9th largest by planned enrollment, is one of 10 that started in 2026, is one of 15 in phase 3, reaches primary completion later than 14 of the 14 other live ones, and was the 27th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States, Greece, Hungary and 3 more countries
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18–64
Novo Nordisk A/S · Sites in Germany
Ages 18–64
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 8 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cagrilintide is the treatment under test here. Read study by study →
36 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 460 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 154 across the 36 interventional studies. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 36 have an industry lead sponsor. The 1 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 34th largest by planned enrollment of the 166 interventional ones that give a count, is one of 47 that started in 2026, is one of 62 in phase 3, reaches primary completion later than 63 of the 65 other live ones, and was the 158th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
8 of the studies testing cagrilintide in Obesity that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011667Phase 3Novo Nordisk A/SA Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | 2027-03-01 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07745504Phase 3Novo Nordisk A/SA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | 2027-05-18 |
| NCT07557953Novo Nordisk A/SA Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity | 2027-04-13 |
Add all 8 to your calendar (.ics) → With an account.
Among the 36 studies testing cagrilintide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to adolescents and adults) or placebo (a placebo looks like the treatment being tested, but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants who get semaglutide in the main study will not take part in the extension study. If participants take part in the extension study, they will get either CagriSema or cagrilintide in this part of the study. Like all drugs, the study drugs may have side effects. The total time participants will be in the main study is about 1 year and 6 months. If participants take part in the extension study, the total time is about 4 years and 10 months.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
This study's planned enrollment of 460 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion criteria:
For participants with T2D at screening the following inclusion criteria also apply
Key exclusion criteria:
For participants with T2D at screening the following exclusion criteria also apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive once weekly subcutaneous (s.c.) dose of CagriSema (cagrilintide and semaglutide) in a dose escalation regimen in the main phase for up to 16 weeks and maintained for 52 weeks and further continue to receive the same dose or maximum tolerated dose (MTD) in the open-label extension phase for up to 156 weeks.
Drug: Cagrilintide · Drug: Semaglutide · Drug: Placebo cagrilintide · Drug: Placebo semaglutide
Participants will receive once weekly s.c. dose of semaglutide in a dose escalation regimen in the main phase for up to 16 weeks and maintained for 52 weeks.
Drug: Semaglutide · Drug: Placebo semaglutide
Participants will receive once weekly s.c. dose of cagrilintide in a dose escalation regimen in the main phase for up to 16 weeks and maintained for 52 weeks, further continue to receive the same dose as the dose escalation regimen or MTD in the open-label extension phase for up to 156 weeks.
Drug: Cagrilintide · Drug: Placebo cagrilintide
Participants will receive once weekly s.c. dose of placebo matched to cagrilintide/semaglutide in a dose escalation regimen in the main phase for up to 16 weeks and maintained for 52 weeks. Participants will further continue to receive the same dose escalation regimen as CagriSema for 16 weeks, later continue to receive the same dose or MTD in the open-label extension phase for up to 140 weeks.
Drug: Placebo cagrilintide · Drug: Placebo semaglutide
Participants will receive cagrilintide subcutaneously.
Participants will receive semaglutide subcutaneously.
Participants will receive placebo matched to cagrilintide subcutaneously.
Participants will receive placebo matched to semaglutide subcutaneously.
Relative change in body mass index (BMI)
Measured in percentage (%).
Time frame: Baseline (week 0), week 68
Relative change in body weight
Measured in %.
Time frame: Baseline (week 0), week 68
Change in BMI Standard Deviation Score (SDS)
Measured as SDS score.
Time frame: Baseline (week 0), week 68
Relative change in BMI
Measured in %.
Time frame: Baseline (week 0), week 68 and week 224
Number of participants in weight category reduction
Measured as count of participants.
Time frame: Baseline (week 0), week 68
Number of participants who achieved greater than or equal to (>=) 5 percent (%) reduction of body weight (yes/no)
Measured as count of participants.
Time frame: Baseline (week 0), week 68
Number of participants who achieved >=10% reduction of body weight (yes/no)
Measured as count of participants.
Time frame: Baseline (week 0), week 68
Number of participants who achieved >=15% reduction of body weight (yes/no)
Measured as count of participants.
Time frame: Baseline (week 0), week 68
Number of participants who achieved >=20% reduction of body weight (yes/no)
Measured as count of participants.
Time frame: Baseline (week 0), week 68
Number of participants who achieved >=25% reduction of body weight (yes/no)
Measured as count of participants.
Time frame: Baseline (week 0), week 68
Number of participants who achieved >=5% reduction of BMI (yes/no)
Measured as count of participants.
Time frame: Baseline (week 0), week 68
Number of participants who achieved >=10% reduction of BMI (yes/no)
Measured as count of participants.
Time frame: Baseline (week 0), week 68
Number of participants who achieved >=15% reduction of BMI (yes/no)
Measured as count of participants.
Time frame: Baseline (week 0), week 68
Number of participants who achieved >=20% reduction of BMI (yes/no)
Measured as count of participants.
Time frame: Baseline (week 0), week 68
Number of participants who achieved >=25% reduction of BMI (yes/no)
Measured as count of participants.
Time frame: Baseline (week 0), week 68
Number of participants who achieved normal BMI
Measured as count of participants.
Time frame: Baseline (week 0), week 68
Number of participants who shifted from obese to non-obese BMI class
Measured as count of participants.
Time frame: Baseline (week 0), week 68
Change in waist circumference
Measured in centimeter (cm).
Time frame: Baseline (week 0), week 68 and week 224
Change in waist-to-height ratio
Measured as ratio.
Time frame: Baseline (week 0), week 68
Absolute change in total fat mass by dual energy X-ray absorption (DXA)
Measured in kilograms (kg).
Time frame: Baseline (week 0), week 68
Relative to baseline change in total fat mass by DXA
Measured in %.
Time frame: Baseline (week 0), week 68
Relative to total body mass change in total fat mass by DXA
Measured in % points.
Time frame: Baseline (week 0), week 68
Absolute change in visceral fat mass by DXA
Measured in kg.
Time frame: Baseline (week 0), week 68
Relative to baseline change in visceral fat mass by DXA
Measured in %.
Time frame: Baseline (week 0), week 68
Relative to total body mass change in visceral fat mass by DXA
Measured in % points.
Time frame: Baseline (week 0), week 68
Absolute change in lean body mass by DXA
Measured in kg.
Time frame: Baseline (week 0), week 68
Relative to total body mass change in lean body mass by DXA
Measured in % points.
Time frame: Baseline (week 0), week 68
Absolute change in total (neck-to-knee) muscle and fat volumes by Magnetic Resonance Imaging (MRI) - total muscle and total fat
Measured in liters (L).
Time frame: Baseline (week 0), week 68 and week 224
Relative to baseline change in total (neck-to-knee) muscle and fat volumes by MRI - total muscle and total fat
Measured in %.
Time frame: Baseline (week 0), week 68 and week 224
Change in ectopic fat content by MRI - liver fat MRI-Proton Density Fat Fraction (MRI-PDFF), pancreatic fat, kidney fat and thigh muscle fat infiltration
Measured in % points.
Time frame: Baseline (week 0), week 68 and week 224
Absolute change in abdominal fat volumes by MRI - subcutaneous fat and visceral fat
Measured in liters.
Time frame: Baseline (week 0), week 68 and week 224
Relative to baseline change in abdominal fat volumes by MRI - subcutaneous fat and visceral fat
Measured in %.
Time frame: Baseline (week 0), week 68 and week 224
Absolute change in thigh muscle and fat volumes by MRI - thigh fat free muscle and thigh subcutaneous fat
Measured in liters.
Time frame: Baseline (week 0), week 68 and week 224
Relative to baseline change in thigh muscle and fat volumes by MRI - thigh fat free muscle and thigh subcutaneous fat
Measured in %.
Time frame: Baseline (week 0), week 68 and week 224
Ratio to baseline in liver stiffness measured by Magnetic Resonance Elastography (MRE)
Measured as ratio.
Time frame: Baseline (week 0), week 68 and week 224
Change in BMI percentage of the 95th percentile
Measured in % points.
Time frame: Baseline (week 0), week 68
Ratio to baseline highly sensitive C-reactive protein (hs-CRP)
Measured as ratio.
Time frame: Baseline (week 0), week 68
Ratio to baseline in lipids: Total cholesterol
Measured as ratio.
Time frame: Baseline (week 0), week 68 and week 224
Ratio to baseline in lipids: High Density Lipoprotein (HDL) cholesterol
Measured as ratio.
Time frame: Baseline (week 0), week 68 and week 224
Ratio to baseline in lipids: Low Density Lipoprotein (LDL) cholesterol
Measured as ratio.
Time frame: Baseline (week 0), week 68 and week 224
Ratio to baseline in lipids: Very Low Density Lipoprotein (VLDL) cholesterol
Measured as ratio.
Time frame: Baseline (week 0), week 68 and week 224
Ratio to baseline in lipids: Triglycerides
Measured as ratio.
Time frame: Baseline (week 0), week 68 and week 224
Ratio to baseline in lipids: Non-HDL cholesterol
Measured as ratio.
Time frame: Baseline (week 0), week 68 and week 224
Change in Alanine Transaminase (ALT)
Measured in Units per Liter (U/L).
Time frame: Baseline (week 0), week 68 and week 224
Change in systolic blood pressure
Measured in millimeters of mercury (mmHg).
Time frame: Baseline (week 0), week 68 and week 224
Change in diastolic blood pressure
Measured in mmHg.
Time frame: Baseline (week 0), week 68 and week 224
Ratio to baseline in liver stiffness measured by ultrasonographic methods
Measured as ratio.
Time frame: Baseline (week 0), week 68 and week 224
Change in glycated haemoglobin (HbA1c) (% points)
Measured in % points.
Time frame: Baseline (week 0), week 68 and week 224
Change in HbA1c (millimoles per mole [mmol/mol])
Measured in mmol/mol.
Time frame: Baseline (week 0), week 68 and week 224
Change in Fasting Plasma Glucose (FPG) (millimoles per liter [mmol/L])
Measured in mmol/L.
Time frame: Baseline (week 0), week 68
Change in FPG (milligrams per deciliter [mg/dL])
Measured in mg/dL.
Time frame: Baseline (week 0), week 68
Ratio to baseline in fasting serum insulin
Measured as ratio.
Time frame: Baseline (week 0), week 68 and week 224
Number of participants with prediabetes who achieved HbA1c less than (<) 5.7% (defined as 5.7 % less than or equal to [<=] HbA1c <6.5 %) at baseline
Measured as count of participants.
Time frame: At week 68
Number of participants with normoglycemia (defined as HbA1c < 5.7 %) at baseline, development of HbA1c greater than or equal to (>=) 5.7 %
Measured as count of participants.
Time frame: At week 68
Number of participants with prediabetes (5.7 % <= HbA1c < 6.5 %) at baseline, development of HbA1c >= 6.5%
Measured as count of participants.
Time frame: At week 68
Number of participants with HbA1c >=6.5% at baseline, achievement of HbA1c <6.5%
Measured as count of participants.
Time frame: At week 68
Number of participants taking glucose lowering medication at baseline, stop or decrease
Measured as count of participants.
Time frame: Baseline (week 0), week 68
Number of participants taking antihypertensive medication at baseline, stop or decrease
Measured as count of participants.
Time frame: Baseline (week 0), week 68
Number of participants taking lipid lowering medication at baseline, stop or decrease
Measured as count of participants.
Time frame: Baseline (week 0), week 68
Impact of Weight on Quality of Life-Kids (IWQOL Kids) - Physical comfort domain score
Measured as score points. IWQOL-Kids measures weight-related quality of life in adolescents (ages 11-19 years) but will be administered to all study participants. The measure consists of 27-items yielding 4 sub-scale scores, and 1 total score. Higher scores indicate better weight-related quality of life. Subscale scores (score range): physical comfort (0-100), body esteem (0-100), social life (0-100), family relations (0-100) and total score (0-100).
Time frame: Baseline (week 0), week 68 and week 224
IWQOL Kids - Body esteem domain score
Measured as score points. IWQOL-Kids measures weight-related quality of life in adolescents (ages 11-19 years) but will be administered to all study participants. The measure consists of 27-items yielding 4 sub-scale scores, and 1 total score. Higher scores indicate better weight-related quality of life. Subscale scores (score range): physical comfort (0-100), body esteem (0-100), social life (0-100), family relations (0-100) and total score (0-100).
Time frame: Baseline (week 0), week 68 and week 224
IWQOL Kids - Social life domain score
Measured as score points. IWQOL-Kids measures weight-related quality of life in adolescents (ages 11-19 years) but will be administered to all study participants. The measure consists of 27-items yielding 4 sub-scale scores, and 1 total score. Higher scores indicate better weight-related quality of life. Subscale scores (score range): physical comfort (0-100), body esteem (0-100), social life (0-100), family relations (0-100) and total score (0-100).
Time frame: Baseline (week 0), week 68 and week 224
IWQOL Kids - Family-relations score
Measured as score points. IWQOL-Kids measures weight-related quality of life in adolescents (ages 11-19 years) but will be administered to all study participants. The measure consists of 27-items yielding 4 sub-scale scores, and 1 total score. Higher scores indicate better weight-related quality of life. Subscale scores (score range): physical comfort (0-100), body esteem (0-100), social life (0-100), family relations (0-100) and total score (0-100).
Time frame: Baseline (week 0), week 68 and week 224
IWQOL Kids - Total score
Measured as score points. IWQOL-Kids measures weight-related quality of life in adolescents (ages 11-19 years) but will be administered to all study participants. The measure consists of 27-items yielding 4 sub-scale scores, and 1 total score. Higher scores indicate better weight-related quality of life. Subscale scores (score range): physical comfort (0-100), body esteem (0-100), social life (0-100), family relations (0-100) and total score (0-100).
Time frame: Baseline (week 0), week 68 and week 224
Control of Eating Questionnaire (COEQ)
Measured as score points. CoEQ is a 19-item multidimensional patient reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving control subscale, the subscale score is reversed so that a higher score represents a greater level of craving control.
Time frame: Baseline (week 0), week 68 and week 224
Change in proteomics-based serum biomarkers including biomarkers for metabolic dysfunction-associated steatohepatitis (MASH)
Measured as counts.
Time frame: Baseline (week 0), week 68 and week 224
Number of treatment-emergent adverse events (TEAEs)
Measured as count of events.
Time frame: Baseline (week 0), week 68 and week 224
Number of treatment-emergent serious adverse events (TESAEs)
Measured as count of events.
Time frame: Baseline (week 0), week 68 and week 224
Number of treatment-emergent hypoglycaemic episodes
Measured as count of events.
Time frame: Baseline (week 0), week 68 and week 224
Change in pulse rate
Measured in beats per minute (beats/min).
Time frame: Baseline (week 0), week 68
Change in calcitonin
Measured in nanograms per liter (ng/L).
Time frame: Baseline (week 0), week 68
Apparent clearance (CL/F) of semaglutide and cagrilintide at steady state
Measured in liters per hour (L/h).
Time frame: Baseline (week 0), week 68
Average concentration (Cavg) of semaglutide and cagrilintide at steady state
Measured in nanomoles per liter (nmol/L).
Time frame: Baseline (week 0), week 68
Area under the steady-state concentration-time curves (AUCt) in the dosing interval of semaglutide and cagrilintide
Measured in hours nanomoles per liter (h·nmol/L).
Time frame: Baseline (week 0), week 68
Not enrolling at this site — choose another above.
Showing the first 100 of 121 sites across 26 countries. Choose a country and city above to see the rest.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on NovoNordisk trials.com.
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Mar 2030, 50 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 50 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cagrilintide